Synaptogenix, Inc. announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment. Bryostatin-1 is a small molecule that works by activating protein kinase C, an enzyme required for maintaining
synapse health, and involved in learning and memory. The therapy may also influence the immune system toward anti-inflammatory efficacy. Preclinical studies have already demonstrated Bryostatin's potential to address cognitive impairment in other neurodegenerative disorders such as Alzheimer's disease, traumatic brain injury,
and Fragile X syndrome. MS may represent a new indication to ameliorate cognitive impairment.